Skip to content

Translating neuronal network hyperexcitability in preclinical familial Alzheimer's disease II

Translating neuronal network hyperexcitability in preclinical familial Alzheimer's disease II - T-REX II

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57648
Enrollment
15
Registered
2025-06-03
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia Neurodegenerative disorder

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Individuals of at least 18 years of age with pathogenic mutations leading to autosomal dominant Alzheimer's disease as confirmed by genetic counseling and with baseline MEG.

Exclusion criteria

Exclusion criteria: Individuals who are or have been treated with (potentially) disease modifying therapies after baseline MEG. Individuals who are not able to travel to the Alzheimer Center Amsterdam or have severe contraindications for undergoing MEG.

Design outcomes

Primary

MeasureTime frame
The main study parameters are obtained by MEG recordings: for both eyes closed, and eyes open resting state, as well as during a working memory task and during light sleep stage. - Hippocampal and whole brain MEG-based measures of oscillatory brain activity, represented as absolute broadband power. - Hippocampal and whole brain MEG-based measures of excitation/inhibition balance (E/I) by the analysis of aperiodic signals (1/f) and the detrended fluctuation analysis (DFA) applied to the amplitude envelope of the conventional frequency bands as proposed measure of E/I ratio (described in Figure 4).

Secondary

MeasureTime frame
- MEG-based measures of oscillatory activity, functional connectivity and network measures in specific frequency bands. - Cognitive performance by score from neuropsychological tests and MMSE and short working memory test during MEG - Structural MRI measurements, such as diffusion tensor imaging (DTI) for structural brain networks characterization, Grey and White matter (G/WM) volumes, FLAIR/SWI for white matter hyperintensities / micro bleeds. - AD biomarkers using CSF based protein concentrations, specifically Aß1-42, total tau and phosphory-lated tau. - Demographics like age, sex, parental age at diagnosis and/or symptom onset, education, mutation type, subjective cognitive complaints and changes, self-reported depression/anxiety, and daily life functioning.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)